|
 |
European Pharmaceutical Contractor
|
| Walfried Laibacher at Honeywell Building Solutions recognises that integrating intelligent building management and process control solutions delivers a measurable return on investment
The life science industry is under enormous pressure to satisfy regulatory compliance and deliver products to market faster than ever before – all the while keeping costs under control. In order to do this, while still maintaining their competitive edge, manufacturers must increase process efficiency, reduce maintenance costs, validate for regulatory compliance and optimise the use of their physical assets. To achieve this, many organisations are now looking to integrate key building management and process control functions.
Process controls featuring automation architectures provide greater visibility and responsiveness throughout the different stages of manufacture. By enabling all relevant information to be accessible from one operating station, these systems can help to manage the manufacturing lifecycle of a product. In addition, automated process control systems can have a significant impact on an organisation’s ability to improve productivity, quality standards and safety.
At the same time, innovative technology emerging from the building automation controls market presents a big opportunity to improve facility and asset management. This includes security, access control, clean room (heating, ventilation and air conditioning/HVAC), energy consumption and asset management, as well as validation frameworks that ensure and prove regulatory compliance.
Traditionally, these automated systems were developed as separate, standalone solutions each with their own monitoring and control station. However, the real power lies in managing them as one intelligent, and integrated, solution. When automated process control and automated building management control systems are integrated, the product development lifecycle can be proactively managed and bring together all the key elements of manufacturing: people, processes, materials, facilities, equipment, documentation and production. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
